Literature DB >> 6182412

Influence of nicardipine on the blood pressure at rest and on the pressor responses to cold, isometric exertion, and dynamic exercise in hypertensive patients.

S H Taylor, B Silke, R C Ahuja, R Okoli.   

Abstract

The dose-response effects of a new slow-calcium-channel blocker, nicardipine, on the resting blood pressure and on the pressor responses induced by skin cold, isometric exertion, and dynamic exercise were examined in a single-blind placebo-controlled study in six male patients with stable uncomplicated essential hypertension. Nicardipine was administered orally in doses of 5 mg, 10 mg, 20 mg, and 20 mg each given three times daily consecutively for 1 week. At the end of each dose period the effects on blood pressure and heart rate at rest and during the three pressor stimuli were measured. There was a significant dose-related reduction in the resting diastolic blood pressure without change in pulse pressure, accompanied by an increase in heart rate. No postural effects on blood pressure were observed. There was a small reduction in the pressor response to hand cold, which was statistically significant at the higher doses. There was no attenuation of the increases in pressure and heart rate induced by handgrip contraction or submaximal treadmill walking at any dose of nicardipine. These results are compatible with direct relaxing effect of the drug on the smooth muscle of the arteriolar resistance vessels without substantial impairment of the sympathetic influences responsible for postural control of the systemic blood pressure or those involved in the pressor responses to the three stimuli tested.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182412     DOI: 10.1097/00005344-198209000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  22 in total

1.  Effect of diuretics and calcium antagonists on circulatory parameters and plasma catecholamines during mental stress.

Authors:  E Heidbreder; K Schafferhans; R Kirsten; A Heidland
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Haemodynamic dose-response effects of i.v. nicardipine in coronary artery disease.

Authors:  B Silke; S P Verma; G I Nelson; M Hussain; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

3.  The effect of acute and chronic nicardipine therapy on forearm arterial haemodynamics in essential hypertension.

Authors:  J Levenson; A C Simon; J Bouthier; B C Maarek; M E Safar
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

4.  Nicardipine hydrochloride in essential hypertension--a controlled study.

Authors:  J Asplund
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

5.  Prevention of vasospastic angina with nicardipine.

Authors:  C J Pepine; J S Gelman
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

6.  Anti-hypertensive dose-response effects of nicardipine in stable essential hypertension.

Authors:  S H Taylor; M A Frais; P Lee; S P Verma; N Jackson; B Silke
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Effect of nicardipine in elderly hypertensive patients.

Authors:  F Forette; M Bellet; J F Henry; M P Hervy; C Poyard-Salmeron; P Bouchacourt; M Guerret
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  The acute haemodynamic effects of nicardipine in patients with chronic left ventricular failure.

Authors:  R A Greenbaum; S Wan; T R Evans
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Cardiovascular, baroreflex and humoral responses in hypertensive patients during nicardipine therapy.

Authors:  P Coruzzi; A Biggi; L Musiari; C Ravanetti; A Novarini
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients.

Authors:  C Cardillo; V Musumeci; L Savi; R Guardigli; N Mores; G Folli
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.